OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
IPO Year: 2017
Exchange: NASDAQ
Website: orthopediatrics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/25/2024 | $39.00 → $31.00 | Buy → Hold | Truist |
3/3/2022 | $83.00 → $65.00 | Buy | Needham |
12/22/2021 | $75.00 → $68.00 | Buy | BTIG |
12/21/2021 | $78.00 → $75.00 | Buy | Truist Securities |
8/6/2021 | $70.00 → $77.00 | Market Outperform | JMP Securities |
WARSAW, Ind., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, has announced a strategic partnership with Children's National Hospital in Washington, DC under the "Alliance for Pediatric Device Innovation" (APDI), to advice the development and commercialization of medical devices designed for children. Along with Children's National, APDI consortium members include Johns Hopkins University, CIMIT at Mass General Brigham, Tufts Medical Center and Medstar Health Research Institute. The Company will serve as APDI's strategic advisor and role model for devic
New CEO Paul Mraz also joins FzioMed Inc.'s Board of Directors; Company set to accelerate growth of market leading Oxiplex® adhesion barrier products. SAN LUIS OBISPO, Calif., Jan. 3, 2023 /PRNewswire/ -- FzioMed, Inc. ("FzioMed" or the "Company"), a global leading surgical biomaterials company focused on spine/orthopedic, peritoneal and gynecological surgery, today announced the appointment of industry veteran Paul Mraz as its new President and CEO and member of the Board of Directors. Mraz's appointment became effective Jan. 1, 2023, commensurate with the retirement of John Krelle who served in the leadership role since 2005. "On behalf of the Board of Directors, I want to thank John for
WARSAW, Ind., Oct. 20, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the appointment of Jimmy D. McDonald to its board of directors, effective October 18, 2022. Mark Throdahl, Executive Chairman of OrthoPediatrics' board said, "We are pleased to have attracted an Operations executive of Jimmy's stature to our company, which has an extensive supplier network of outsourced products. Beyond his directly relevant experience, Jimmy brings a wonderful personal fit with the culture of our board and our company." Mr. McDonald currently is Vice Pr
WARSAW, Ind., June 03, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the senior leadership transition, with David Bailey succeeding Mark Throdahl as Chief Executive Officer. Mark Throdahl will remain with the Company as Executive Chairman. "Over the last 10 years, it has been a privilege to work with our remarkable team leading the effort to improve the lives of children suffering from musculoskeletal disorders," said Mark Throdahl. "As Executive Chairman, I look forward to remaining highly engaged with OrthoPediatrics and its strategy as wel
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13D/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13D/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
10-Q - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
10-Q - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Business Highlights Helped a record of more than 33,000 children in the third quarter 2024, an increase of 50% from the third quarter 2023Generated record total revenue of $54.6 million for the third quarter of 2024, up 37% from $40.0 million in third quarter 2023; domestic revenue increased 45% and international revenue increased 12% in the quarterGrew w
WARSAW, Ind., Oct. 23, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
WARSAW, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the launch of its Enabling Technologies division. The Enabling Technologies division will leverage the company's core mission of addressing unmet pediatric needs in orthopedics and apply this focus to new areas within digital health and advanced technology. Led by industry veteran, Kevin Unger, this new division is set to differentiate OrthoPediatrics' core business, generate sustainable revenue growth, and access new markets and specialties beyond orthopedics. OrthoPediatrics has already ma
WARSAW, Ind., Aug. 20, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced plans to host an investor day at 10:30am E.T. on September 12, 2024, in New York, New York. Management's presentation will provide updates on the Company's Specialty Bracing business strategy, product pipeline, and financial outlook and feature a KOL surgeon panel. Investors interested in attending the event may request to register by contacting the investor relations department at [email protected] by September 6, 2024. The presentation will also be webcast live and a r
WARSAW, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Business Highlights Helped a record 32,000 children in the second quarter of 2024, an increase of 52% from the second quarter 2023Generated record total revenue of $52.8 million for the second quarter of 2024, up 33% from $39.6 million in second quarter 2023; domestic revenue increased 39% and international revenue increased 16% in the quarterGrew worldwide Trauma & Deformity
WARSAW, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has signed a private financing arrangement with Braidwell LP consisting of a term loan and private placement of convertible notes that will provide up to $100 million of capital. The financing is expected to fund on or about August 12, 2024. OrthoPediatrics' COO & CFO, Fred Hite, commented, "This financing strengthens our balance sheet at a more attractive cost of capital. This capital also provides additional flexibility to execute our strategic growth initiatives where one of our top pri
WARSAW, Ind., July 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2024 financial results on Monday, August 5, 2024, after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 6, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be ava
WARSAW, Ind., June 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer is scheduled to participate in a fireside chat at the Truist Securities MedTech Conference, being held in Boston, MA. Event:Truist Securities MedTech ConferenceFormat:Fireside ChatDate:Tuesday, June 18, 2024Time:4:45 pm ET An audio webcast of the discussion will be available online at the OrthoPediatrics' investor relations website, http://ir.orthopediatrics.com. Additionally, a replay will be available after the event.
WARSAW, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support of the combined 2024 Pediatric Orthopaedic Society of North America ("POSNA") and European Paediatric Orthopaedic Society ("EPOS") annual meeting as an Emerald sponsor. At the Annual Meeting, the Company highlighted its growing portfolio of pediatric-specific solutions at its exhibit booth. The Company sponsored a session focused on decision-making in the orthopedic management of neuromuscular patients led by physicians from Boston Children's, Nemours Children's Health, a
WARSAW, Ind., May 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Business Highlights Helped nearly 28,000 children in the first quarter of 2024, an increase of 47% from the first quarter 2023Generated total revenue of $44.7 million for the first quarter of 2024, up 41% from $31.6 million in first quarter 2023; domestic revenue increased 44% and international revenue increased 33% in the quarterGrew worldwide Trauma & Deformity revenue 42%, wo
Truist Securities analyst Samuel Brodovsky maintains OrthoPediatrics (NASDAQ:KIDS) with a Hold and lowers the price target from $38 to $35.
Truist Securities analyst Samuel Brodovsky maintains OrthoPediatrics (NASDAQ:KIDS) with a Hold and raises the price target from $35 to $38.
7 analysts have expressed a variety of opinions on OrthoPediatrics (NASDAQ:KIDS) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 1 0 0 Last 30D 1 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 2 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for OrthoPediatrics, presenting an average target of $40.29, a high estimate of $50.00, and a low estimate of $32.00. Witnessing a positi
Needham analyst Mike Matson maintains OrthoPediatrics (NASDAQ:KIDS) with a Buy and raises the price target from $37 to $42.
JMP Securities analyst David Turkaly reiterates OrthoPediatrics (NASDAQ:KIDS) with a Market Outperform and maintains $50 price target.
OrthoPediatrics (NASDAQ:KIDS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.40) by 25 percent. This is a 3.45 percent decrease over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $44.685 million which beat the analyst consensus estimate of $41.775 million by 6.97 percent. This is a 41.46 percent increase over sales of $31.588 million the same period last year.
OrthoPediatrics Corp. ("OrthoPediatrics") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has received the "Breakthrough Device" Designation from the Food and Drug Administration ("FDA") for its new eLLi surgical device, an implant designed to address severe pathology associated with Early Onset Scoliosis (EOS), which can be associated with thoracic insufficiency, a potentially life-threatening condition. eLLi aims to provide a non-invasive means of extending the growing rods that provides increased force, enhanced mechanical reliability, and superior distraction precision, while also addressing safety concerns associated with
Analysts' ratings for OrthoPediatrics (NASDAQ:KIDS) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 2 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 1 1 0 0 3M Ago 0 0 1 0 0 Analysts have set 12-month price targets for OrthoPediatrics, revealing an average target of $36.83, a high estimate of $50.00, and a low estimate of $31.00. Observing a 8.32% increase, the current average has risen from the pr
Needham analyst Mike Matson reiterates OrthoPediatrics (NASDAQ:KIDS) with a Buy and maintains $37 price target.
WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Business Highlights Helped a record of more than 33,000 children in the third quarter 2024, an increase of 50% from the third quarter 2023Generated record total revenue of $54.6 million for the third quarter of 2024, up 37% from $40.0 million in third quarter 2023; domestic revenue increased 45% and international revenue increased 12% in the quarterGrew w
WARSAW, Ind., Oct. 23, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
WARSAW, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Business Highlights Helped a record 32,000 children in the second quarter of 2024, an increase of 52% from the second quarter 2023Generated record total revenue of $52.8 million for the second quarter of 2024, up 33% from $39.6 million in second quarter 2023; domestic revenue increased 39% and international revenue increased 16% in the quarterGrew worldwide Trauma & Deformity
WARSAW, Ind., July 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2024 financial results on Monday, August 5, 2024, after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 6, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be ava
WARSAW, Ind., May 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Business Highlights Helped nearly 28,000 children in the first quarter of 2024, an increase of 47% from the first quarter 2023Generated total revenue of $44.7 million for the first quarter of 2024, up 41% from $31.6 million in first quarter 2023; domestic revenue increased 44% and international revenue increased 33% in the quarterGrew worldwide Trauma & Deformity revenue 42%, wo
WARSAW, Ind., April 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2024 financial results on Monday, May 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Tuesday, May 7, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available
WARSAW, Ind., March 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 & Recent Business Highlights Helped nearly 20,000 children in the fourth quarter 2023 and approximately 82,000 for full year 2023, bringing the total to over 710,000 since the inception of OrthoPediatrics, including Boston Orthotics & Prosthetics, the combined organizations have helped more than 1.0 million kidsGenerated total revenue of $37.6 million for fo
WARSAW, Ind., Feb. 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2023 financial results on Wednesday, March 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Thursday, March 7, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The w
Combined organizations have helped more than 1 million kids Expands Specialty Bracing Division with pediatric orthotic management business offering leading technology and pediatric care through dedicated clinics Closes $80 million debt financing to support acquisition and future business requirements WARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it has acquired Boston Orthotics & Prosthetics ("Boston O&P"), a leader in pediatric orthotic management for over 50 years. Additionally, in advance of the acquisition, th
WARSAW, Ind., Nov. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2023. Third Quarter 2023 and Business Highlights Helped over 22,000 children in the third quarter of 2023, bringing the total to over 692,000 since inception including MD Orthopaedics ("MD Ortho") and Pega MedicalGenerated total revenue of $40.0 million for the third quarter of 2023, up 14% from $35.0 million in third quarter 2022; domestic revenue increased 11% and international revenue increased 26% in t
Truist downgraded OrthoPediatrics from Buy to Hold and set a new price target of $31.00 from $39.00 previously
Needham reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $65.00 from $83.00 previously
BTIG reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $68.00 from $75.00 previously
Truist Securities reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $75.00 from $78.00 previously
JMP Securities reiterated coverage of OrthoPediatrics with a rating of Market Outperform and set a new price target of $77.00 from $70.00 previously
Needham reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $77.00 from $70.00 previously